Your browser doesn't support javascript.
loading
Outcome definitions for multidrug-resistant tuberculosis treated with shorter treatment regimens.
Schwoebel, V; Chiang, C-Y; Trébucq, A; Piubello, A; Aït-Khaled, N; Koura, K G; Heldal, E; Van Deun, A; Rieder, H L.
Afiliação
  • Schwoebel V; International Union Against Tuberculosis and Lung Disease, Paris, France.
  • Chiang CY; International Union Against Tuberculosis and Lung Disease, Paris, France, Division of Pulmonary Medicine, Department of Internal Medicine, Wanfang Hospital, Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Ta
  • Trébucq A; International Union Against Tuberculosis and Lung Disease, Paris, France.
  • Piubello A; International Union Against Tuberculosis and Lung Disease, Paris, France.
  • Aït-Khaled N; International Union Against Tuberculosis and Lung Disease, Paris, France.
  • Koura KG; International Union Against Tuberculosis and Lung Disease, Paris, France, Institut de Recherche pour le Développement, Mère et Enfant face aux Infections tropicales, Paris 5 University, Sorbonne Paris Cité, Paris, France.
  • Heldal E; International Union Against Tuberculosis and Lung Disease, Paris, France.
  • Van Deun A; International Union Against Tuberculosis and Lung Disease, Paris, France, Institut de Médecine Tropicale, Anvers, Belgium.
  • Rieder HL; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Tuberculosis Consultant Services, Kirchlindach, Switzerland.
Int J Tuberc Lung Dis ; 23(5): 619-624, 2019 05 01.
Article em En | MEDLINE | ID: mdl-31097072
ABSTRACT
id="st1"> OBJECTIVE To assess whether the revised 2013 World Health Organization (WHO) definitions for multidrug-resistant tuberculosis (MDR-TB) treatment outcomes apply to shorter treatment regimens in low- and middle-income countries and to propose modified criteria. id="st2"> <a class="decs" id="22045">METHODS</a> Criteria for 'failure' and 'cure' outcomes were assessed using data on 1006 patients enrolled in an observational study on the standardised 9-11 month shorter MDR-TB regimen in Africa. id="st3"> RESULTS Absence of conversion in the intensive phase, a WHO criteria for failure, was the worst performing criterion; reversion had low sensitivity and other criteria provided limited added value. Based on our study results, we propose new definitions for 'treatment failure' as treatment termination or the permanent discontinuation of 2 anti-tuberculosis drugs due to 1) positive culture after 6 months of treatment (except for one isolated positive culture) or 2) at least two consecutive grade 2+ positive sputum smears after 6 months of treatment if culture is not available; and for 'cure' as treatment completion without proof of failure AND two consecutive negative cultures taken 30 days apart, one of which should be after 6 months of treatment. id="st4"> CONCLUSION The proposed new definitions are applicable to shorter regimens in low- and middle-income countries, and should also work for the newly recommended longer regimens. .
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose Resistente a Múltiplos Medicamentos / Antituberculosos Tipo de estudo: Clinical_trials / Observational_studies Limite: Adult / Humans País/Região como assunto: Africa Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose Resistente a Múltiplos Medicamentos / Antituberculosos Tipo de estudo: Clinical_trials / Observational_studies Limite: Adult / Humans País/Região como assunto: Africa Idioma: En Ano de publicação: 2019 Tipo de documento: Article